Original Research

Advances in Therapy

, Volume 31, Issue 1, pp 107-117

Efficacy of Sublingual Fentanyl vs. Oral Morphine for Cancer-Related Breakthrough Pain

  • Ignacio Velázquez RiveraAffiliated withUnidad del Dolor del Hospital de Alta Resolución de Guadix Email author 
  • , José Carlos Muñoz GarridoAffiliated withUnidad del Dolor del Hospital Comarcal de Melilla
  • , Pilar García VelascoAffiliated withUnidad del Dolor del Hospital de Alta Resolución de Guadix
  • , Inmaculada España Ximénez de EncisoAffiliated withUnidad del Dolor del Hospital Comarcal de Melilla
  • , Lourdes Velázquez ClavaranaAffiliated withCentro Gámez Morón de Melilla

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Introduction

Breakthrough cancer pain (BTcP) is recognized as a clinically significant complication of chronic cancer pain with most BTcP episodes peaking in intensity within a few minutes and lasting for approximately 30 min. Although a number of rapid-onset fentanyl preparations have been developed in the last decade, BTcP is still typically managed through the use of rescue doses of oral morphine but a comparative study of sublingual fentanyl and oral morphine is still lacking. The aim of this study was to determine the efficacy, tolerability, and patient satisfaction of sublingual fentanyl citrate (SLF) and oral morphine solution (OM) in the treatment of BTcP.

Methods

In this prospective, longitudinal, controlled-study, 40 patients with BTcP were allocated to receive oral morphine (OM) or sublingual fentanyl (SLF). Pain intensity level on a 0–10 numerical rating visual analog scale (VAS), frequency of BTcP throughout the day, onset of relief (0–5, 6–10, 11–15, or over 16 min), time required for dose titration, patient satisfaction and adverse effects were assessed at 3, 7, 15, and 30 days after starting the treatment.

Results

Mean doses of opioids for BTcP were 235 ± 23.4 μg (SLF) and 38 ± 5.2 mg (OM). The mean pain intensity levels were significantly lower with SLF than OM at 3 days (6.0 vs. 6.95; p = 0,001), 7 days (4.15 vs. 6.25, p < 0.001), 15 days (3.45 vs. 5.35, p < 0.001), and 30 days (3.05 vs. 4.45, p < 0.001). SLF provided significantly faster relief for BTcP than OM (p < 0.001) with a shorter dose titration period (mean 6.6 ± 3.3 vs. 13.3 ± 4.9 days; p < 0.001) and better satisfaction scores and with a very good safety profile.

Conclusions

Administration of SLF might provide a more effective treatment option than oral morphine for BTcP.

Keywords

Breakthrough pain Cancer Oncology Oral morphine Sublingual fentanyl